is the fda banning compounded tirzepatide Tirzepatide: Legal & Safe 2025 FDA bans compounded GLP1 medications,
Description
Sitagliptin Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone In a 24-week placebo-controlled trial of sitagliptin 100 mg administered once daily added to a twice daily metformin regimen, there were no adverse reactions reported regardless of investigator assessment of causality in 5% of patients and more commonly than in patients given placebo
Pratley RE, Nauck MA, Barnett AH, et al
Make sure you are using a U-100 syringe, not a U-40 or U-50
The medication is not approved for intravenous or intramuscular use, and the effects of accidental intravenous injection are unknown
Work with your provider to find the optimal approach for your stage of treatment
Lifestyle-Only Approach: A structured plan focusing on nutrition, activity, and behaviour can still support steady weight loss without medication
